Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Feb;84(2):499–510. doi: 10.1111/j.1476-5381.1985.tb12934.x

Depolarization-induced release of propranolol and atenolol from rat cortical synaptosomes.

P S Bright, T E Gaffney, J A Street, J G Webb
PMCID: PMC1987298  PMID: 3919793

Abstract

The accumulation and release of [3H]-propranolol and [3H]-atenolol were examined in synaptosomes from rat cerebral cortex. Synaptosomes accumulated 20 pmol propranolol and 0.6 pmol atenolol mg-1 protein when incubated at 30 degrees C with radiolabelled drugs (0.1 microM). Exposure of propranolol-loaded synaptosomes to elevated K+, Rb+ or Cs+ evoked a concentration-dependent increase in propranolol efflux. The action of these ions in releasing propranolol was highly correlated with their ability to produce synaptosomal membrane depolarization, as estimated with the voltage-sensitive dye diS-C3-(5). Elevated K+ also promoted atenolol release from synaptosomes in a concentration-dependent manner. Veratridine (10 microM) released propranolol and atenolol from synaptosomes and these effects were antagonized by tetrodotoxin (1 microM). Under Ca2+-free conditions, K+-induced release of propranolol was reduced by 37% and atenolol release was diminished by 68%. The results support the concept that both polar and non-polar beta-adrenoceptor blocking drugs may be accumulated by nerve endings for release by membrane depolarization and suggest that neural storage and release of these molecules may influence their concentrations at localized sites of action.

Full text

PDF
499

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amery A., De Plaen J. F., Lijnen P., McAinsh J., Reybrouck T. Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther. 1977 Jun;21(6):691–699. doi: 10.1002/cpt1977216691. [DOI] [PubMed] [Google Scholar]
  2. Barber H. E., Hawksworth G. M., Kitteringham N. R., Petersen J., Petrie J. C., Swann J. M. Protein binding of atenolol and propranolol to human serum albumin and in human plasma [proceedings]. Br J Clin Pharmacol. 1978 Nov;6(5):446P–447P. [PubMed] [Google Scholar]
  3. Blaustein M. P., Goldring J. M. Membrane potentials in pinched-off presynaptic nerve ternimals monitored with a fluorescent probe: evidence that synaptosomes have potassium diffusion potentials. J Physiol. 1975 Jun;247(3):589–615. doi: 10.1113/jphysiol.1975.sp010949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Catterall W. A. Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Annu Rev Pharmacol Toxicol. 1980;20:15–43. doi: 10.1146/annurev.pa.20.040180.000311. [DOI] [PubMed] [Google Scholar]
  5. Costain D. W., Green A. R. beta-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. Br J Pharmacol. 1978 Oct;64(2):193–200. doi: 10.1111/j.1476-5381.1978.tb17289.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cruickshank J. M. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980 Aug;100(2):160–178. doi: 10.1016/0002-8703(80)90112-x. [DOI] [PubMed] [Google Scholar]
  7. Dachary-Prigent J., Dufourcq J., Lussan C., Boisseau M. Propranolol, chlorpromazine and platelet membrane: a fluorescence study of the drug-membrane interaction. Thromb Res. 1979 Jan;14(1):15–22. doi: 10.1016/0049-3848(79)90020-3. [DOI] [PubMed] [Google Scholar]
  8. Daniell H. B., Walle T., Gaffney T. E., Webb J. G. Stimulation-induced release of propranolol and norepinephrine from adrenergic neurons. J Pharmacol Exp Ther. 1979 Mar;208(3):354–359. [PubMed] [Google Scholar]
  9. Deutsch C., Rafalowska U. Transmembrane electrical potential measurements in rat brain synaptosomes. FEBS Lett. 1979 Dec 1;108(1):274–278. doi: 10.1016/0014-5793(79)81227-2. [DOI] [PubMed] [Google Scholar]
  10. Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor. Nature. 1977 May 19;267(5608):289–290. doi: 10.1038/267289a0. [DOI] [PubMed] [Google Scholar]
  11. Dollery C. T., Junod A. F. Concentration of (+/-)-propranolol in isolated, perfused lungs of rat. Br J Pharmacol. 1976 May;57(1):67–71. doi: 10.1111/j.1476-5381.1976.tb07657.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. GRAY E. G., WHITTAKER V. P. The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. J Anat. 1962 Jan;96:79–88. [PMC free article] [PubMed] [Google Scholar]
  13. Godin D. V., Ng T. W., Tuchek J. M. Studies on the interaction of propranolol with erythrocyte membranes. Biochim Biophys Acta. 1976 Jul 15;436(4):757–773. doi: 10.1016/0005-2736(76)90404-1. [DOI] [PubMed] [Google Scholar]
  14. Green A. R., Johnson P., Nimgaonkar V. L. Interactions of beta-adrenoceptor agonists and antagonists with the 5-hydroxytryptamine2 (5-HT2) receptor. Neuropharmacology. 1983 May;22(5):657–660. doi: 10.1016/0028-3908(83)90159-4. [DOI] [PubMed] [Google Scholar]
  15. Haycock J. W., Levy W. B., Denner L. A., Cotman C. W. Effects of elevated [K+]O on the release of neurotransmitters from cortical synaptosomes: efflux or secretion? J Neurochem. 1978 May;30(5):1113–1125. doi: 10.1111/j.1471-4159.1978.tb12406.x. [DOI] [PubMed] [Google Scholar]
  16. Hemsworth B. A., Street J. A. Characteristics of (+/-)-[14C]-oxprenolol and (+/-)-[14C]-propranolol incorporation by rat lung slices. Br J Pharmacol. 1981 May;73(1):119–125. doi: 10.1111/j.1476-5381.1981.tb16780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Henry D. P., Starman B. J., Johnson D. G., Williams R. H. A sensitive radioenzymatic assay for norepinephrine in tissues and plasma. Life Sci. 1975 Feb 1;16(3):375–384. doi: 10.1016/0024-3205(75)90258-1. [DOI] [PubMed] [Google Scholar]
  18. Herbette L., Katz A. M., Sturtevant J. M. Comparisons of the interaction of propranolol and timolol with model and biological membrane systems. Mol Pharmacol. 1983 Sep;24(2):259–269. [PubMed] [Google Scholar]
  19. Horn A. S. Structure-activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopaminergic neurones in rat brain homogenates. Br J Pharmacol. 1973 Feb;47(2):332–338. doi: 10.1111/j.1476-5381.1973.tb08331.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hurwitz G. A., Webb J. G., Walle T., Bai S. A., Daniell H. B., Gourley L., Boyd Loadholt C., Gaffney T. E. Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol. 1983 Dec;16(6):599–608. doi: 10.1111/j.1365-2125.1983.tb02228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Huunan-Seppälä A. Binding of propranolol and chlorpromazine by mitochondrial membranes. Acta Chem Scand. 1972;26(7):2713–2733. doi: 10.3891/acta.chem.scand.26-2713. [DOI] [PubMed] [Google Scholar]
  22. Iversen L. L., Bloom F. E. Studies of the uptake of 3 H-gaba and ( 3 H)glycine in slices and homogenates of rat brain and spinal cord by electron microscopic autoradiography. Brain Res. 1972 Jun 8;41(1):131–143. doi: 10.1016/0006-8993(72)90621-x. [DOI] [PubMed] [Google Scholar]
  23. Kamino K., Inouye A. Evidence for membrane potential changes in isolated synaptic membrane ghosts monitored with a merocyanine dye. Jpn J Physiol. 1978;28(2):225–237. doi: 10.2170/jjphysiol.28.225. [DOI] [PubMed] [Google Scholar]
  24. Kostrzewa R. M., Jacobowitz D. M. Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev. 1974 Sep;26(3):199–288. [PubMed] [Google Scholar]
  25. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  26. Lee A. G. Local anesthesia: the interaction between phospholipids and chlorpromazine, propranolol, and practolol. Mol Pharmacol. 1977 May;13(3):474–487. [PubMed] [Google Scholar]
  27. Lewis M. J. Effect of acute and chronic treatment with practolol on cardiovascular responses in the pithed rat. J Pharm Pharmacol. 1974 Oct;26(10):783–788. doi: 10.1111/j.2042-7158.1974.tb09174.x. [DOI] [PubMed] [Google Scholar]
  28. Ljung B., Ablad B., Dahlöf C., Henning M., Hultberg E. Impaired vasoconstrictor nerve function in spontaneously hypertensive rats after long-term treatment with propranolol and metroprolol. Blood Vessels. 1975;12(5):311–315. doi: 10.1159/000158067. [DOI] [PubMed] [Google Scholar]
  29. Lüllmann H., Wehling M. The binding of drugs to different polar lipids in vitro. Biochem Pharmacol. 1979 Dec 1;28(23):3409–3415. doi: 10.1016/0006-2952(79)90080-7. [DOI] [PubMed] [Google Scholar]
  30. Marquardt G. M., DiStefano V., Ling L. L. Effects of racemic, (S)- and (R)-methylenedioxyamphetamine on synaptosomal uptake and release of tritiated norepinephrine. Biochem Pharmacol. 1978 May 15;27(10):1497–1501. doi: 10.1016/0006-2952(78)90106-5. [DOI] [PubMed] [Google Scholar]
  31. Meyer E. M., Cooper J. R. High affinity choline uptake and calcium-dependent acetylcholine release in proteoliposomes derived from rat cortical synaptosomes. J Neurosci. 1983 May;3(5):987–994. doi: 10.1523/JNEUROSCI.03-05-00987.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Müller W. E., Stillbauer A. E. Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid). Naunyn Schmiedebergs Arch Pharmacol. 1983 Mar;322(2):170–173. doi: 10.1007/BF00512392. [DOI] [PubMed] [Google Scholar]
  33. Noble E. P., Wurtman R. J., Axelrod J. A simple and rapid method for injecting H3-norepinephrine into the lateral ventricle of the rat brain. Life Sci. 1967 Feb 1;6(3):281–291. doi: 10.1016/0024-3205(67)90157-9. [DOI] [PubMed] [Google Scholar]
  34. Ota M., Narahashi T., Keeler R. F. Effects of veratrum alkaloids on membrane potential and conductance of squid and crayfish giant axons. J Pharmacol Exp Ther. 1973 Jan;184(1):143–154. [PubMed] [Google Scholar]
  35. Rudnick G., Bencuya R., Nelson P. J., Zito R. A., Jr Inhibition of platelet serotonin transport by propranolol. Mol Pharmacol. 1981 Jul;20(1):118–123. [PubMed] [Google Scholar]
  36. Russell M. P., Webb J. G., Walle T., Daniell H. B., Privitera P. J., Gaffney T. E. Adrenergic nerve stimulation-induced release of propranolol from the perfused hindlimb and spleen of the dog and associated changes in postjunctional response. J Pharmacol Exp Ther. 1983 Aug;226(2):324–329. [PubMed] [Google Scholar]
  37. Saelens D. A., Daniell H. B., Webb J. G. Studies on the interactions of propranolol with adrenergic neurons. J Pharmacol Exp Ther. 1977 Sep;202(3):635–645. [PubMed] [Google Scholar]
  38. Sieghart W., Heckl K. Potassium-evoked release of taurine from synaptosomal fractions of rat cerebral cortex. Brain Res. 1976 Nov 12;116(3):538–543. doi: 10.1016/0006-8993(76)90503-5. [DOI] [PubMed] [Google Scholar]
  39. Sims P. J., Waggoner A. S., Wang C. H., Hoffman J. F. Studies on the mechanism by which cyanine dyes measure membrane potential in red blood cells and phosphatidylcholine vesicles. Biochemistry. 1974 Jul 30;13(16):3315–3330. doi: 10.1021/bi00713a022. [DOI] [PubMed] [Google Scholar]
  40. Street J. A., Webb J. G., Bright P. S., Gaffney T. E. Accumulation, subcellular localization and release of propranolol from synaptosomes of rat cerebral cortex. J Pharmacol Exp Ther. 1984 Apr;229(1):154–161. [PubMed] [Google Scholar]
  41. Surewicz W. K., Leyko W. Interaction of propranolol with model phospholipid membranes. Monolayer, spin label and fluorescent spectroscopy studies. Biochim Biophys Acta. 1981 May 6;643(2):387–397. doi: 10.1016/0005-2736(81)90083-3. [DOI] [PubMed] [Google Scholar]
  42. Tauc L. Non vesicular release of neurotransmitter. Physiol Rev. 1982 Jul;62(3):857–893. doi: 10.1152/physrev.1982.62.3.857. [DOI] [PubMed] [Google Scholar]
  43. Vestal R. E., Kornhauser D. M., Shand D. G. Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines. J Pharmacol Exp Ther. 1980 Jul;214(1):106–111. [PubMed] [Google Scholar]
  44. Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther. 1978 Dec;24(6):668–677. doi: 10.1002/cpt1978246668. [DOI] [PubMed] [Google Scholar]
  45. Wood M. D., Wyllie M. G. Critical assessment of noradrenaline uptake in synaptosomal preparations. Naunyn Schmiedebergs Arch Pharmacol. 1983 Mar;322(2):129–135. doi: 10.1007/BF00512385. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES